Table 2.

Baseline variables associated with near-remission at 6 months stratified for the missing item (PGA or SJC28).

	SJC28 near-remission n = 77	PGA near-remission n = 48	p
Demographic
Age, mean (SD)	59 (15.1)	59.9 (15.3)	0.75
Female gender, n (%)	56 (72.7)	34 (70.8)	0.98
Disease characteristics
Duration, weeks, mean (SD)	21.4 (21)	20.2 (22.1)	0.79
RA 1987 criteria, n (%)	62 (80.5)	38 (79.2)	0.96
Disease activity
SJC28, mean (SD)	8.3 (5)	6 (3.8)	0.01*
TJC28, mean (SD)	4.7 (4.4)	6 (5.2)	0.14
PhGA, mean (SD)	4.6 (2)	4.3 (2)	0.53
DAS28, mean (SD)	4.67 (1.12)	4.65 (1.29)	0.92
SDAI, mean (SD)	24.89 (10.96)	24.80 (10.43)	0.97
PROs
VAS pain, mean (SD)	50.1 (28.3)	53.3 (29.2)	0.55
PGA, mean (SD)	5.2 (3)	5.2 (2.8)	0.99
HAQ, mean (SD)	1.02 (0.66)	1.2 (0.97)	0.21
Laboratory
ESR, mean (SD)	32.1 (21)	28.2 (22.4)	0.33
CRP, mean (SD)	1.69 (2.02)	1.19 (1.44)	0.14
RF positive, n (%)	47 (61)	11 (22.9)	<0.001*
ACPA positive, n (%)	38 (49.4)	11 (22.9)	0.005*
RF and/or ACPA positive, n (%)	56 (72.7)	15 (31.2)	<0.001*
Imaging
Erosion SHS score ⩾1, n (%)	34 (44.2)	17 (35.4)	0.43
US-GS score, mean (SD)	8.2 (6.4)	7.3 (5.1)	0.44
US-PD score, mean (SD)	5.9 (6.6)	5.7 (5.2)	0.89

^*Significant at p < 0.05.

ACPA, anti-citrullinated protein antibodies; CRP, C-reactive protein; DAS28, disease activity score on 28 joints; ESR, erythrocyte sedimentation rate; GS, gray scale; HAQ, health assessment questionnaire; IQR, interquartile range; PD, power Doppler; PGA, patient global assessment; PhGA, physician global assessment; PROs, patient reported outcomes; RF, rheumatoid factor; SD, standard deviation; SDAI, simplified disease activity index; SHS, Sharp van der Heijde score; SJC28, swollen joint count on 28 joints; TJC28, tender joint count on 28 joints; US, ultrasonography; VAS, visual analogue scale.